ORG 31550

Drug Profile

ORG 31550

Alternative Names: SR 80027; SR 80027A

Latest Information Update: 08 Jan 2001

Price : $50

At a glance

  • Originator Organon; Sanofi-Synthelabo
  • Class Antithrombotics; Glycosaminoglycans; Oligosaccharides
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 08 Jan 2001 Discontinued-Preclinical for Thrombosis in Netherlands (Unknown route)
  • 08 Jan 2001 Discontinued-Preclinical for Thrombosis in France (Unknown route)
  • 27 Aug 1999 Sanofi has merged with Synthélabo to form Sanofi-Synthélabo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top